Gemcitabine (Gemzar) / CDC25 Cancer Research Results

GEM, Gemcitabine (Gemzar): Click to Expand ⟱
Features: Chemo
GEM An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA
Treats cancer of pancreas, lung, ovary and breast.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Inhibition of DNA synthesis (antimetabolite effect) Incorporated into DNA → chain termination Normal dividing cells affected (bone marrow, GI epithelium) P, R, G Direct cytotoxicity Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is phosphorylated to the triphosphate form (dFdCTP) which competes with dCTP, gets incorporated into DNA, and blocks DNA chain elongation.
2 Ribonucleotide reductase (RNR) inhibition dFdCDP inhibits RNR → deoxynucleotide pool depletion ↔ (normal proliferating cells also impacted) R, G Nucleotide pool imbalance Gemcitabine diphosphate (dFdCDP) inhibits RNR, reducing available dNTPs and enhancing the chain-termination effect.
3 Apoptosis induction (DNA damage response) DNA damage signaling → caspase activation Toxicity in dividing normal tissues G Execution of cell death Prolonged DNA synthesis arrest and replication stress triggers apoptosis pathways via ATR/Chk1, p53, and caspase cascades.
4 Cell-cycle arrest (S-phase accumulation) S-phase arrest steers cells into apoptosis ↔ G Cytostasis → death Accumulation of stalled replication forks enforces S-phase arrest and amplifies cytotoxicity.
5 DNA damage response signaling (ATR/Chk1/Chk2) Checkpoint activation ↔ R, G Damage signaling Replication stress activates ATR/Chk1/Chk2 and modulates cell-cycle checkpoints and repair responses.
6 NF-κB pro-survival signaling (resistance axis) NF-κB activation can reduce sensitivity ↔ R, G Resistance/modulation In some tumor models, NF-κB and other pro-survival axes mediate resistance to gemcitabine cytotoxicity; inhibition sensitizes cells.
7 Autophagy modulation (response to stress) Autophagy ↑ in some contexts (cytoprotective) ↔ G Adaptive stress response Gemcitabine can induce autophagy as a survival mechanism in some models; autophagy inhibition can sensitize cells in combination studies.
8 Reactive oxygen species (ROS) elevation (indirect) ROS ↑ (reported in some models) ↔ G Stress amplification Some preclinical studies report ROS increases secondary to replication stress; not a primary mechanism but modulates cell-death pathways.
9 Clinical resistance mechanisms (CDA, nucleoside transporters) CDA ↑; hENT1 ↓ correlates with resistance — G Resistance / exposure constraint Cytidine deaminase (CDA) inactivates gemcitabine; lower hENT1 transport reduces uptake — major clinical resistance factors.
10 Bioavailability / pharmacokinetics (IV dosing; systemic exposure) IV infusion achieves systemic levels ↔ — PK constraint Gemcitabine is given systemically (often IV) and achieves cytotoxic blood levels; rapid deamination by CDA and short half-life shape dosing.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid biochemical activation / early metabolic engagement)
  • R: 30 min–3 hr (acute nucleotide pool effects / checkpoint signaling)
  • G: >3 hr (DNA damage response, cell death, phenotype outcomes)
CDC25, Cell Division Cycle 25: Click to Expand ⟱
Source:
Type:
CDC25 (Cell Division Cycle 25) is a family of dual-specificity phosphatases that play a crucial role in regulating the cell cycle. There are three main isoforms of CDC25: CDC25A, CDC25B, and CDC25C. These proteins are involved in the activation of cyclin-dependent kinases (CDKs) by dephosphorylating them, which is essential for the progression of the cell cycle from G2 phase to mitosis.
CDC25 proteins, particularly CDC25A, are often found to be overexpressed in various types of cancer. This overexpression can lead to uncontrolled cell proliferation, as the normal regulatory mechanisms of the cell cycle are disrupted.
High levels of CDC25 have been associated with advanced stages of cancer and poor prognosis in several malignancies, including breast, colorectal, and prostate cancers.
CDC25 interacts with various oncogenes and tumor suppressor proteins, such as p53. The loss of p53 function, which is common in many cancers, can lead to increased CDC25 activity, further promoting tumorigenesis.
CDC25A overexpressed: breast, CRC, lung, prostate.
CDC25B: breast, ovarian, lung.
CDC25C: liver,breast, prostate.
Scientific Papers found: Click to Expand⟱
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NQO1?, 1,  

Mitochondria & Bioenergetics ⓘ

CDC25↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   cl‑Casp3↑, 1,   p‑Chk2↑, 1,   TUNEL↑, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   tumCV↓, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT?, 1,   HDAC↓, 1,   TumCG↓, 1,  

Migration ⓘ

Ki-67↓, 1,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

eNOS↓, 1,   Hif1a↓, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  
Total Targets: 23

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: CDC25, Cell Division Cycle 25
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:84  Target#:526  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page